Many new therapeutic targets for the treatment of bipolar disorder are currently being investigated. These include drug targets and therapies established to treat other psychiatric disorders, targets and therapies established primarily for non-psychiatric indications, including anti-inflammatory agents and ...
Bipolar Disorder PatientLithium is the most effective and well established treatment for bipolar disorder, and it has a broad array of effects within cellular pathways. However, the specific processes through which therapeutic effects occur and are maintained in bipolar disorder remain unclear. This ...
Bipolar Disorder (BD) is characterized by mood swings that cause significant impairment in social, occupational, or other areas of functioning. During the last years, new insights have been provided in the diagnosis, etiology, neurobiological basis and treatment of bipolar disorder. This paper emphasi...
Integration of suicide prevention into outpatient management of bipolar disorder Suicide prevention is a critical objective in the treatment of bipolar disorder. This article describes practical mechanisms by which monitoring and manage... GS Sachs,LJ Yan,AC Swann,... - 《Journal of Clinical Psychiatr...
Developing Therapeutic Alternatives for Treatment-resistant Bipolar Depression: The Role of Riluzole doi:10.4274/tjcamh.galenos.2020.92485BIPOLAR disorderMETHYL aspartateTurkish Journal of Child & Adolescent Mental Health / ocuk ve Genlik Ruh Sagligi Dergisipür, Sidarpür, ...
These advances have provided a means to produce proteins previously available in limited supply and allow for the production of novel proteins t... JD Baxter - 《Medical Clinics of North America》 被引量: 8发表: 1991年 Review of novel therapeutic targets for improving heart failure treatment ...
Substantial progress has been made towards the development of effective therapies and treatments for the multiple forms of Batten disease. In 2017, cerliponase alfa (Brineura), a tripeptidyl peptidase enzyme replacement therapy, became the first globally approved treatment for CLN2 Batten disease. ...
, suggesting thatSTIP1augmentation may be a feasible strategy for antidepressant treatment; however, the detailed underlying mechanisms remain unclarified. Study limitations This study has several limitations. First, it is possible that differences in gene expression between MDD patients and controls ...
Pharmacokinetic monitoring is not routine in the treatment of psychiatric disorders, although subtherapeutic or toxic plasma concentrations of psychotropic agents can result from standard doses because of interindividual variability of drug metabolism. Therapeutic plasma concentrations have been established for ...
[105]. This provides evidence towards potentially using ASOs to inhibit NMD ofMECP2, thus opening a therapeutic avenue for the treatment of Rett syndrome. However, it is again important to noteMECP2dosage sensitivity as a significant roadblock to a successful treatment. Additionally, further ...